Federated Hermes
ABUS icon

Federated Hermes’s Arbutus Biopharma ABUS Stock Holding History

Federated Hermes’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.4K Buy
+4,041
New +$17.7K ﹤0.01% 1783
2024
Q4 		– Sell
-3
Closed -$12 – 2069
2024
Q3 		$12 Buy
+3
New +$12 ﹤0.01% 2045
2024
Q2 		– Sell
-11,033
Closed -$28.5K – 2020
2024
Q1 		$28.5K Buy
+11,033
New +$28.6K ﹤0.01% 1685
2021
Q4 		– Sell
-619
Closed -$3K – 2197
2021
Q3 		$3K Sell
619
-514
-45% -$1.71K ﹤0.01% 2060
2021
Q2 		$3K Buy
1,133
+137
+14% +$424 ﹤0.01% 2064
2021
Q1 		$3K Buy
+996
New +$3.84K ﹤0.01% 2088
2018
Q4 		– Sell
-563
Closed -$5K – 2184
2018
Q3 		$5K Buy
563
+10
+2% +$99 ﹤0.01% 2048
2018
Q2 		$4K Buy
+553
New +$3.29K ﹤0.01% 2031

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Federated Hermes's ABUS Position: Q2 2026 in Review

Federated Hermes opened a new position in Arbutus Biopharma (ABUS) in Q2 2026: 4,041 shares worth $19.4K. The stake represents ﹤0.01% of the portfolio and ranks #1783 among its holdings. This is a return to the name: Federated Hermes previously reported a position in ABUS as recently as Q3 2024.

Federated Hermes first reported a position in ABUS in Q2 2018 and has held it in 8 quarters since. The position peaked at $28.5K in Q1 2024. 176 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • Federated Hermes held 4,041 shares of Arbutus Biopharma worth $19.4K as of Q2 2026.
  • Arbutus Biopharma was a new Federated Hermes position in Q2 2026.
  • Arbutus Biopharma made up ﹤0.01% of Federated Hermes's portfolio in Q2 2026, its #1783 holding.
  • Federated Hermes first reported a position in Arbutus Biopharma in Q2 2018 and has held it in 8 quarters since.
  • Federated Hermes's Arbutus Biopharma position peaked at $28.5K in Q1 2024.
  • 176 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.